A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
- 1 August 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (9) , 1373-1379
- https://doi.org/10.1016/s0959-8049(96)00413-3
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cost Effectiveness of Adjuvant Intraportal Chemotherapy in Patients with Colorectal CancerJournal of Clinical Gastroenterology, 1996
- Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancerEuropean Journal of Clinical Pharmacology, 1996
- Assessment of Quality-of-Life OutcomesNew England Journal of Medicine, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Cost-effectiveness of Interferon-α2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1995
- The Cost Effectiveness of Preoperative Autologous Blood DonationsNew England Journal of Medicine, 1995
- Results of adjuvant interferon study In WHO melanoma programmeThe Lancet, 1994
- Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1991
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989